Posts Tagged ‘liposarcoma’
DAMASCUS, Md. – May 28, 2020 – The Sarcoma Foundation of America (SFA), an organization dedicated to increasing research and awareness for sarcoma, today announced that it has awarded three-quarters of a million dollars in research funds to deserving scientists as part of its 2020 SFA Research Grant program. Fifteen research grants, each worth $50,000, have been awarded to researchers who have made it their mission to study sarcoma, a cancer that arises in the body’s soft tissue and bone. All proposals are peer reviewed by members of the SFA Medical Advisory Board who award the grants to the best,… Read More »
Sarcoma is a rare type of cancer and typically produces malignant tumors derived from the connective tissue. There are more than 70 sarcoma types and subtypes. Soft Tissue Sarcoma Soft tissue sarcoma broadly defines cancers that develop in the body’s soft tissues (i.e. muscles, tendons, fat, lymph vessels, blood vessels, and nerves). While these cancers are most commonly found in the head, neck, arms, legs, chest, and abdomen, they can develop anywhere in the body. There are various different types of soft tissue sarcoma, and depending on the type of soft tissue the cancer started in, the cells will look… Read More »
Andrew Koff, PhD, Member and Professor, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center 2014 Heidi Connery Memorial Research Grant: “Proteomic and genomic approaches to understanding intrinsic and acquired resistance to CDK4 inhibition therapy in well differentiated/dedifferentiated liposarcoma” PLEASE DESCRIBE THE FOCUS OF THE RESEARCH PERFORMED IN YOUR LAB. The laboratory of cell cycle regulation at Memorial Sloan Kettering Cancer Center is interested in identifying the genes and proteins that regulate the transition of cells from quiescence, a reversible type of proliferative exit, to senescence, a more stable irreversible type of proliferative exit. Proliferation associated with a deregulated cell cycle… Read More »
-Drug Approved for Use in Treatment of Advanced Liposarcoma and Leiomyosarcoma- DAMASCUS, Md. – October 23, 2015 – The Sarcoma Foundation of America (SFA) applauds the announcement by the Food and Drug Administration (FDA) that the drug Yondelis (trabectedin, marketed by Janssen) has been approved by the agency for the treatment of advanced liposarcoma and leiomyosarcoma, two subtypes of soft tissue sarcoma. Yondelis has received approval for the use in the treatment of patients with unresectable or metastatic liposarcoma and leiomyosarcoma who have previously received an anthracycline chemotherapy. “The Sarcoma Foundation of America is thrilled with the FDA’s decision to approve… Read More »